Coinbase CEO: The Future of Crypto, Machine-to-Machine Payments and the Quest to Live Forever

What It Covers

Coinbase CEO Brian Armstrong covers the evolution of crypto from a niche concept to a global financial infrastructure, explaining how stablecoins, tokenization, and machine-to-machine payments are reshaping finance, while discussing AI adoption inside Coinbase and his longevity biotech venture, New Limit.

Key Questions Answered

• •Stablecoin Advantage: Stablecoins are the only payment rail that simultaneously delivers low cost (under one-tenth of a cent per transaction), speed (under one second), and global reach. Every other major system — credit cards at 2–3% fees, SWIFT at 2–3 business days — fails at least one of these three dimensions, making stablecoins structurally superior for cross-border payments.
• •Machine-to-Machine Payments: AI agents cannot open bank accounts, but they can hold stablecoin wallets. Coinbase's x402 protocol, launched five months before this recording, enables AI agents to pay for services, transact with other agents, and execute tasks autonomously. It has already processed 100 million transactions, signaling a potential orders-of-magnitude increase in daily transaction volume.
• •AI Adoption Playbook: Armstrong drove AI tool adoption at Coinbase by setting a hard deadline for all engineers to sign up and try tools like Cursor and Claude within one week. He monitored adoption rates numerically and held a Saturday CEO meeting for non-adopters. Result: over 50% of code is now AI-written and 60% of customer support tickets are AI-resolved.
• •Stablecoin Scale vs. Bank Deposits: Banks holding $3 trillion at the Federal Reserve and $7 trillion sitting in money market funds dwarfs the current $300 billion stablecoin market cap. Armstrong uses this ratio to counter claims that stablecoins threaten bank deposits, arguing the order-of-magnitude difference makes stablecoins a negligible competitive threat to traditional deposit bases in the near term.
• •Longevity Escape Velocity Timeline: Armstrong co-founded biotech company New Limit, focused on epigenetic reprogramming — restoring cells to younger functional states. Within three years, the company demonstrated successful reprogramming of human cells and targets its first clinical drug trial in 2026. Armstrong estimates a 50% probability that longevity escape velocity, where each year lived gains another year of life expectancy, arrives within his lifetime.